Price Crosses Moving Average
|Bid||5.10 x 900|
|Ask||5.21 x 1300|
|Day's Range||5.10 - 5.40|
|52 Week Range||2.25 - 12.89|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is sticking to its business plan, despite any disruption from the pandemic. Meetings with regulators are on the schedule, and preparatory work for its approval filing continues. First quarter results were in-line with estimates. Research and development rose to $0.9 million in the quarter,
By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross-linked formulation of sodium hyaluronate (HA). 2019 was a turning point for EyeGate Pharmaceuticals. In March, 2019, the
Benzinga Pro's Stocks To Watch For Friday Tesla (TSLA) - Shares were down about 3% to under the $350 level following Thursday evening's unveiling of the company's new pickup, the Cybertruck. Uber (UBER) ...
By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT OBG-PRK: Pivotal Data Upcoming, 2020 Launch Feasible OBG-PE: Pre-Pivotal Study Moving Quick, Pivotal in 2020? We continue to be encouraged by the recent rapid and consistent progress of both the OBG-PRK and OBG-PR programs. The quick pace the ongoing studies follows speediness in nailing down clinical site, trial design and
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...
Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes. "We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From.
By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT FDA Approves IDE for OBG-PRK Pivotal Study, Topline Results Expected Later This Year… The major recent news on the operating front was ...